The aim was to evaluate the effectiveness of a progressive program, starting with simple methods and, when not effective, moving to more complex methods, to treat erectile dysfunction (ED) in patients with diabetes mellitus. A total of 284 diabetic patients with ED entered into a 6-phase program starting with sildenafil citrate (Viagra). Those with contraindications, side effects, or negative response (erection insufficient for vaginal penetration) were switched to the vacuum erection device (VED), and then progressively (for failures) to intracavernous injection (ICI), sildenafil citrate þ ICI, ICI þ VED, and penile prosthesis. Patients were followed for 2 y. Of the 284 patients 276 patients were eligible for sildenafil citrate and 147 (53.3%) responded positively, but 25 (9.1%) patients stopped it soon due to adverse effects. Of 162 patients (129 nonresponders, eight noneligible for the sildenafil and 25 patients who dropped out due to adverse effects), treated with VED, 114 (70.4%) responded well, however, only 19 (11.7%) patients agreed to continue its use. Of the remaining 143 patients (nonresponders, noneligible for the previously mentioned treatments and patients who dropped out due to adverse effects), 103/143 (72%) responded to ICI, 27/40 (67.5%) to sildenafil þ ICI, and 9/13 (69.2%) to ICI þ VED. Four patients received a penile implant. At the 2 y follow-up, 81 of 284 patients who entered the study (28.5%) were still responding to sildenafil, seven (2.5%) to VED, 113 (39.8%) to ICI, 24 (8.5%) to sildenafil þ ICI, two (0.7%) to ICI þ VED; 15 (5.3%) had a penile implant. In all 17 (6%) patients reported spontaneous erections, 11 (3.9%) stopped the treatment due to family reasons and 14 (4.9%) failed the treatment. In conclusion, the progressive treatment program for ED seems to be very effective for diabetic patients, yielded a complete response for short-term and 91.2% rate of success at the end of 2 y follow-up.
Introduction
Diabetes mellitus (DM) is one of most common diseases. Its prevalence in US varies from 1-2 to 6.6% of general population, depending on chosen criteria of DM.
1 DM is associated with erectile dysfunction (ED) in 25-75% of men, depending on age, duration of DM, glycemic control, presence of microvascular (retinopathy, nephropathy and neuropathy) and macrovascular (ischemic heart disease, peripheral vascular disease and cerebro-vascular disease) complications. [2] [3] [4] [5] The mechanism underlying ED in patients with DM is usually multifactorial. Neuropathy, atherosclerosis of big vessels, endothelial dysfunction of small vessels, hormonal imbalance, comorbid diseases, physiological stress and various medications may be involved in the pathogenesis of ED in patients with DM. 2, 5 Of course, the usual causes of ED in general population, like depression, postsurgery, etc, may also play a role in patients with DM. All these factors need to be taken into account in treating ED in this population.
There are several methods currently available for the treatment of ED associated with DM, including the vacuum erection device (VED); 6, 7 intracavernous injection (ICI) of vasoactive drugs; [8] [9] [10] oral phosphodiesterase inhibitors such as sildenafil citrate (Viagra), 11 tadalafil citrate (Cialis) 12 and vardenafil (Levitra); 13 combination of sildenafil with VED 14 or ICI of vasoactive drugs; 15 and penile prosthesis. 16 However, the studies conducted so far have evaluated the success of each method of treatment alone. The aim, of the present study was to examine the effectiveness of a stepwise, progressive ED treatment program in a large cohort of patients with diabetes mellitus.
Patients and methods
The study group consisted of 284 consecutive patients with DM referred to our tertiary center for the treatment of ED between 1998 and 2002. All patients had DM type II that was diagnosed before the entrance into the study according to fasting glucose level or oral glucose tolerance test. The demographic characteristics of the patients as well as the data regarding the duration of DM and their comorbidities are presented in Table 1 . In all, 43 patients (15.1%) were treated by insulin alone or with combination with oral hypoglycemic agents at the time of the study. The rest of the patients received oral hypoglycemic agents only. DM was relatively controlled.
The diagnosis of ED was based on the International Index of Erectile Function (IIEF). 17 Medical, social and psychosexual history of the patients and their partners were taken. Physical examination, nocturnal penile tumescence test with Rigiscan, penile color Doppler ultrasound and penile electrothermometry 18 were performed. Complete blood count, electrolytes, glucose level, liver enzymes, urea and creatinine, level of prostate-specific antigen, prolactin and total testosterone were checked. No untreated hormonal disbalances in the hypothalamic-hypopituitary-testicular axis were found in our study group, because our department is a tertiary center and all the possible hormonal problems were identified and treated before the reference.
Procedure
A positive response at all phases of the program was defined as an erection sufficient for vaginal penetration.
Phase 1.
Patients without contraindications 19 were offered sildenafil citrate (Viagra), one tablet at 1 h before coitus, 2-3 h after a meal, at a starting dose of 25-50 mg, depending on age. The dose was increased to 50 and 100 mg at intervals of 2-4 days, depending on response, age, and general state of health.
Phase 2. Patients with contraindications to sildenafil, adverse drug effects, or a negative response (to at least 3-5 doses of 100 mg) were offered vacuum therapy with the VED. Details of its applications were explained to the patients individually before commencing. Silicone cream or lubricating gel was applied around the root of the penis, and the cylinder (with constriction rings) was opened and placed on the penis. Negative pressure was applied slowly and gradually over 2-3 min. When the patient reported pain, we removed the cylinder, but left the constriction rings in place for an additional 1-2 min. Two sessions were conducted by the same operators at intervals of 2-3 days. In patients with a positive response, the device was recommended for use at home before coitus.
Phase 3. VED failures were switched to ICI with cocktail of trimix of vasoactive drugs: papaverine 12-25 mg þ phentolamine 1.0-2.0 mg þ prostaglandin E1 6-25 mg. In patients who complained of pain during erection, the prostaglandin E1 dose was decreased and the doses of the other drugs were increased.
Phase 4.
Patients who failed to respond to the ICI were given sildenafil citrate 50-100 mg followed 40-55 min later by a ICI of papaverine 25 mg þ phentolamine 2 mg þ prostaglandin E1 6-25 mg. Note: All values given in n (%) unless otherwise indicated.
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Phase 5. In patients who failed phase 4, we attempted ICI with papaverine, 16 mg, phentolamine 1.5 mg, and prostaglandin E1 15-25 mg, followed 5-10 min later by the VED.
Phase 6. In patients who did not respond to phase 5, we recommended penile implant surgery.
Follow-up
All patients were followed for 2 y. ED treatment was changed during follow-up, as necessary, according to the same 6-phase program. Follow-up consisted of physical examinations for general state of health, IIEF score, and laboratory tests. In patients receiving the ICI, the physical examination also included a search for palpable fibrotic nodules. Penile Doppler color ultrasound and nocturnal penile tumescence test were repeated.
Statistical analysis
The results immediately after treatment and at the end of follow-up were analyzed according to Bland. 20 Arithmetic mean values and errors of the mean or median values were calculated. Statistical differences were determined with Student's t-test. Values of Po0.05 were considered significant.
Results
Analysis of the IIEF scores before the treatment showed that 126 patients (44.4%) had severe ED, 106 (37.3%) moderate ED, and 52 (18.3%) mildmoderate ED. Five patients (1.8%) have had ED for 6 months to 1 y, 38 (13.4%) for 1-2 y, 117 (41.2%) for 2-5 y, 88 (31%) for 5-10 y, and 36 (12.7%) for 10-14 y. Mean duration was 2.570.9 y. Treatment (Table 2) Phase 1. Of the 284 patients, eight were excluded from the sildenafil citrate phase as a precaution because of intensive laser treatment for severe retinopathy on the basis of ophtalmologist's request. Of the remaining 276 patients receiving sildenafil citrate, a positive response was noted in 147 (53.3%). In all, 25 patients (9.1%) had adverse effects, including facial flushing (n ¼ 12, 4.3%), headache (n ¼ 9, 3.3%), dizziness (n ¼ 3, 1.1%), and abnormal vision (n ¼ 1, 0.4%) and stopped sildenafil citrate after short time. Therefore 122 (44.2%) patients were able to continue this treatment.
Phase 2. Vacuum therapy with the VED was attempted in 162 patients: 129 who failed to respond to sildenafil citrate þ 25 with adverse effects to sildenafil þ 8 with retinopathy. After 2-3 sessions at intervals of 2-3 days, 114 patients (70.4%) showed a positive response. In all, 13 of them (8%), however, complained of severe pain from even the largest tension ring, and in 17 (10.5%) decreased penile rigidity to 1-2 min even with the smallest ring. Only 19 (11.7%) agreed to use the VED under domestic conditions. Phase 3. A total of 143 patients were given ICI with vasoactive drugs: 48 patients who failed phase 2, 30 who had pain or rigidity during VED, 65 who refused the VED for home use despite a good response.
In all, 64 patients (44.8%) responded positively to the first ICI dose of papaverine 12 mg þ phentolamine 1 mg þ prostaglandin E1 10 mg. The duration of the response was 65.673.2 min. An additional 66 patients (46.2%) responded to the ICI, but had pain during erection. In these cases, the dose of prostaglandin E1 was reduced to 6 mg, and the doses of papaverine and phentolamine were increased to 17 and 1.5 mg, respectively. In the nonresponders to the first injection, the dose of prostaglandin E1 was increased as well, to 12.274.5 mg. There were 29/79 (36.7%) responders 
In all, 17 (42.5%) patients responded, with a response duration of 48.575.5 min. A total of 23 nonresponders received sildenafil 100 mg followed by ICI at the same doses. In all, 10 patients (25%) responded to this increased dose with response duration of 31.471.2 min. Four patients (17.4%) complained of slight dizziness. A total of 13 patients were considered as nonresponders in this phase.
Phase 5. In all, 13 patients went on to receive papaverine 16 mg þ phentolamine 1.5 mg þ prostaglandin E1 15.273.4 mg followed by the VED. After two sessions at intervals of 3-5 days, nine (69.2%) showed a positive response.
Phase 6. The remaining four patients agreed to an inflatable two-piece (three patients) or three-piece (one patient) penile prosthesis. All performed successful coitus 8-10 weeks after surgery.
Of the 43 patients receiving insulin, 37 were eligible for sildenafil citrate treatment, and nine (24.3%) responded. In all, 22 (64.7%) of 34 responded to the ICI, 4/12 (33.3%) to sildenafil þ the ICI, 2/8 (25%) to ICI þ VED and the remaining four underwent a penile implant. Of the 17 patients (70.6%) in whom penile rigidity decreased after VED, 12 were receiving insulin.
Follow-up
During the 2 y follow-up after 284 patients, the ED treatment was changed as necessary, according to the same 6-phase program. The reasons for transition from one treatment modality to another were different. In all, 11 patients were referred for penile implantation due to failure of other options during this period of time. Of the 19 patients (63.2%) who received the VED, 12 were asked to switch to another form of treatment during follow-up because their partner complained of a cold sensation during vaginal penetration. Examination of these patients in glands penis with an electrothermometer showed that at 1-2 min before vacuum therapy, penile temperature was 30.470.91C, and after 10-12 min, it dropped to 24.470.41C (Po0.05). After ICI in 6/113 patients (5.3%), small nodules appeared and treatment was stopped for 1.0-1.5 months, during which time vacuum therapy was used. The nodules disappeared within this period in all patients.
At the end of 2 y, 81 of 284 patients who entered the study (28.5%) were performing successful coitus with sildenafil citrate, seven (2.5%) with VED, 113 (39.8%) with ICI, 24 (8.5%) with sildenafil þ ICI, two (0.7%) with ICI þ VED and 15 (5.3%) with a penile prosthesis. In all, 17 (6%) patients reported spontaneous erections. A total of 14 (5%) patients had a negative response to all treatments. All of them had diabetic complications and comorbidities, including six (42.9%) receiving insulin, aged 70-78 y. In all, 11 (3.9%) patients stopped treatment despite an initial positive response: five were divorced, two were widowed, and four had an ill wife. In general, after 2 y, 259 (91.2%) were achieving coitus.
Total mean IIEF score before treatment was 16.4876.41, and after 2 y of follow-up, 58.647 11.78 (Po0.001). Comparison of the mean response to five domains of the IIEF between baseline and termination of the 2 y follow-up is shown in Table 3 .
Doppler ultrasound was performed in 17 patients with decreased rigidity with rings (VED). Peak systolic velocity (mean7s.d.) before ICI was 16.77 1.5 cm/s, after 5 min 46.672.8 cm/s (Po0.001), after 15 min 24.371.6 cm/s (Po0.0001). Peak diastolic velocity before ICI was 3.570.2, after 5 min 8.970.3 (Po0.05) and after 15 min 4.270.4 cm/s (Po0.05). We assumed these patients had venous leakage. Accordingly, in the 12 patients who reported spousal complaints of cold sensation, electrothermometry revealed a significant drop from 
Discussion
Our team first applied a progressive treatment program for ED in diabetic patients in 1997. In 1998, the US Food and Drug Administration approved the use of sildenafil citrate (Viagra), which was then incorporated into our program, after its contraindications were clarified. 19 In the present study, a progressive program for the treatment of ED in diabetic patients yielded a complete response for short-term and 91.2% rate of success at the end of 2 y follow-up. Sildenafil and ICI were the most common modalities.
The analysis of a group of 276 patients who received sildenafil shows that 147 (53.3%) responded positively, including nine of 37 (24.3%) receiving insulin. The rate of side effects was 9.1%. A review of the findings in the literature yielded a 62.9% positive response rate in 465 patients with DM evaluated by Carson et al, 21 and a 64.6% rate in the study of Boulton et al, 11 including 36.8% positivity among patients taking insulin. The discrepancy with our results may be explained by the high percentage of diabetic complications and comorbidities in our sample (61.1%), the older age of our sample (43.7% of the patients were in the 61-78 y age group), and the relatively high (13.4%) rate of insulin use. The rate of adverse effects in our study is in line with others. 8, 9, 20 Our response rate for the VED (70.4%), as well as the percentage of patients 4, 5 with pain, decreased rigidity and temperature are similar to the reports of others investigators. 17, 22 Color Doppler ultrasound in 17 patients with penile rigidity at 1-2 min after cylinder removal showed a significant difference in peak systolic and peak diastolic velocity from 5 min after ICI to 15 min after, similar to the findings of Sarteschi et al.
23
In the present study, 143 patients received different doses of three vasoactive drugs. Using a dimix of papaverine 30 mg þ phentolamine 1.5 mg in patients with DM, Bell et al 8 reported a success rate of 36.4%. Segenreich et al 9 achieved a success rate of 67.4% with papaverine þ Regitine in 198 diabetic patients. The use of prostaglandin E1 for failures of the dimix yielded a 41.4% response rate. However, 30.6% of patients reported various grades of pain during erection. The remaining patients with a negative response were given all three drugs trimix, and 64.5% achieved successful coitus. Accordingly, our success rate with the ICI was 72%; after 2 y of follow-up, 39.8% of the patients were still responding to it. Our rate of pain was also high, however (46.2%). We reduced the dose of prostaglandin E1 in the patients with pain. (For this reason, the prostaglandin E1 dose is given throughout as mean7s.d.)
Sildenafil þ the ICI, our phase 4, was used for the treatment of ED by McMahon et al 15 in patients who failed sildenafil alone; 47.5% had a positive response. Adverse effects of different severities occurred in 31%. Our success rate with this method was 67.5%; during follow-up, 10% of patients had adverse effects. Our higher positive response may be explained by the more effective dosage used in the present study, namely, papaverine 25 mg, phentolamine 2.0 mg, prostaglandin E1 15.475.6 mg. Our lower rate of adverse effects may be explained by lower mean dose of sildenafil.
Use of the ICI followed after 5-10 min by the VED was reported by Chen et al, 14 who noted a mean change in buckle pressure of 117.0738.5 g after ICI and of 565.0758.6 g after VED (Po0.0001). We also found the method to be highly effective, yielding a positive response in nine of 13 patients (69.2%). By the end of follow-up, however, this method was used only by two patients (22.2%), mainly because of the complexity of the method and its unsuitability for patients without a regular partner, decrease of temperature in penis especially in glands penis.
Penile implant surgery, which was successful in 15 patients in our study, including 12 (80%) in whom penile rigidity decreased after removal of the VED cylinder and three (20%) who stopped using the VED because their spouse found it uncomfortable, was also found by Carson et al 16 to yield a good response in diabetic patients. The penile prosthesis, however, is associated with a risk of infection, especially in patient receiving insulin, 24 as were six of our patients. Our high surgical success rate was probably attributable to our use of intraoperative antibiotic irrigation and extensive preand postoperative administration of antibiotics.
Interestingly, Grunwald et al 25 found no statistically significant change in the retinal vasculature in 15 otherwise healthy men aged 3978 y using the highest dose (100 mg) of sildenafil citrate on a voluntary basis. Nevertheless, we did not want to risk giving the drug to our eight patients with retinopathy and hypertension. Two of them (25%) responded to the VED, and six to the ICI.
Of the 17 patients who reported spontaneous erections at follow-up, 11 (64.7%) patients had mild-moderate ED before the start of the treatment, and six had moderate ED. None had comorbidities, all were less than 60 y old, and all were married. In all, 12 of them (70.6%) had received the ICI and five (29.4%) sildenafil citrate during the treatment period.
In conclusion, the stepwise, progressive treatment program for ED in patients with mild-to-severe DM proved seems to be very effective yielding in a complete response for short-term and 91.2% rate of success at the end of 2 y follow-up. The more Treatment of erectile dysfunction in diabetic patients S Israilov et al complex, invasive treatments (phases 3-6) were needed mainly by patients taking insulin or with comorbid diseases. Most of the patients who failed to respond on follow-up were older (aged 70-78 y) and had other diseases besides diabetes.
